Your browser does not support flash 8 or later which is needed to view this animation. Please visit www.macromedia.com/go/getflashplayer to download the flash player.

1. Wilhelm SM, Carter C. Tang LY, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res. 2004;64:7099-7109.
2. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interaction. Biochem J. 2000;351:289-305.
3. McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Advan Enzyme Regul. 2006;46:249-279.
4. Lee HC, Tian B, Sedivy JM, Wands JR, Kim M. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology. 2006;131:1208-1217.
5. Osada S, Kanematsu M, Imai H, Goshima S, Sugiyama Y. Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma. J Am Coll Surg. 2005;201:405-411.
6. Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther. 2005;4(4):677-685.
7. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor–targeted therapy in renal cell carcinoma. J Clin Oncol. 2005;23(5):1028-1043.
8. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res. 2004;10(suppl):6388S-6392S.

Next: Professional Resources

 

Term

Explanation for term.